Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Ohkawa R, Nakamura K, Yanagisawa N, Tsuboi S, Ogita M, Yokoyama K, Kurata T, Yatomi Y, Daida H.

Atherosclerosis. 2011 Dec;219(2):907-12. doi: 10.1016/j.atherosclerosis.2011.09.019. Epub 2011 Sep 17.

PMID:
22024276
2.

Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?

Gu X, Hou J, Yang S, Yu H, Tian J, Liu F, Li N, Yu B, Jang IK.

Coron Artery Dis. 2014 Jan;25(1):10-5. doi: 10.1097/MCA.0000000000000041.

PMID:
24089018
3.

Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.

Ohashi T, Shibata R, Morimoto T, Kanashiro M, Ishii H, Ichimiya S, Hiro T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura T, Daida H, Murohara T, Matsuzaki M.

Atherosclerosis. 2010 Sep;212(1):237-42. doi: 10.1016/j.atherosclerosis.2010.05.005. Epub 2010 May 11.

PMID:
20684825
4.

Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

Maiolino G, Pedon L, Cesari M, Frigo AC, Wolfert RL, Barisa M, Pagliani L, Rossitto G, Seccia TM, Zanchetta M, Rossi GP.

PLoS One. 2012;7(10):e48171. doi: 10.1371/journal.pone.0048171. Epub 2012 Oct 31.

5.

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.

Jabor B, Choi H, Ruel I, Hafiane A, Mourad W, Genest J.

Can J Cardiol. 2013 Dec;29(12):1679-86. doi: 10.1016/j.cjca.2013.09.026. Epub 2013 Oct 2.

PMID:
24267807
6.

Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial.

Hibi K, Kimura T, Kimura K, Morimoto T, Hiro T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Saito S, Yamaguchi T, Daida H, Matsuzaki M; JAPAN-ACS Investigators.

Atherosclerosis. 2011 Dec;219(2):743-9. doi: 10.1016/j.atherosclerosis.2011.08.024. Epub 2011 Aug 22.

PMID:
21899843
7.

Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.

Takashima H, Ozaki Y, Morimoto T, Kimura T, Hiro T, Miyauchi K, Nakagawa Y, Yamagishi M, Daida H, Mizuno T, Asai K, Kuroda Y, Kosaka T, Kuhara Y, Kurita A, Maeda K, Amano T, Matsuzaki M; JAPAN-ACS Investigators.

Circ J. 2012;76(12):2840-7. Epub 2012 Sep 7.

8.

Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.

Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Kadota K, Kimura K, Hirayama A, Kimura K, Hasegawa Y, Uchiyama S, Matsuzaki M; JAPAN-ACS Investigators.

Circ J. 2012;76(4):825-32.

9.

Evaluation of lipoprotein-associated phosholipase A2 and plaque burden/composition in young adults.

Celik O, Ozturk D, Akin F, Satilmis S, Yalcin AA, Erturk M, Ayca B, Akturk F, Birand A, Pusuroglu H, Kaya MG.

Coron Artery Dis. 2015 May;26(3):266-71. doi: 10.1097/MCA.0000000000000224.

PMID:
25647459
10.

Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.

Gajos G, Zalewski J, Mostowik M, Konduracka E, Nessler J, Undas A.

Nutr Metab Cardiovasc Dis. 2014 Apr;24(4):434-9. doi: 10.1016/j.numecd.2013.09.011. Epub 2013 Nov 1.

PMID:
24555913
11.

Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study).

Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, Kasai H, Izawa A, Tomita T, Koyama J, Ikeda U.

Circ J. 2011;75(3):633-41. Epub 2011 Jan 24.

12.

The different association of epicardial fat with coronary plaque in patients with acute coronary syndrome and patients with stable angina pectoris: analysis using integrated backscatter intravascular ultrasound.

Harada K, Harada K, Uetani T, Kataoka T, Takeshita M, Kunimura A, Takayama Y, Shinoda N, Kato B, Kato M, Marui N, Ishii H, Matsubara T, Amano T, Murohara T.

Atherosclerosis. 2014 Oct;236(2):301-6. doi: 10.1016/j.atherosclerosis.2014.07.007. Epub 2014 Jul 28.

PMID:
25117765
13.

Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.

Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Sekikawa A, Kadota A, Kadowaki S, Nakamura Y, Miyagawa N, Okamura T, Kita Y, Takashima N, Kashiwagi A, Maegawa H, Horie M, Yamamoto T, Kimura T, Kita T; ACCESS and SESSA Research Groups.

Atherosclerosis. 2016 Mar;246:141-7. doi: 10.1016/j.atherosclerosis.2015.12.027. Epub 2015 Dec 23.

PMID:
26775119
14.

Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study.

Kashiyama K, Sonoda S, Muraoka Y, Suzuki Y, Kamezaki F, Tsuda Y, Araki M, Tamura M, Takeuchi M, Abe H, Okazaki M, Fujino Y, Otsuji Y.

Int J Cardiovasc Imaging. 2015 Jun;31(5):935-45. doi: 10.1007/s10554-015-0633-y. Epub 2015 Feb 28.

15.

Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.

Xu RX, Zhang Y, Li XL, Li S, Guo YL, Dong Q, Liu G, Li JJ.

Clin Chim Acta. 2015 Jun 15;446:195-200. doi: 10.1016/j.cca.2015.04.032. Epub 2015 Apr 28.

PMID:
25934512
17.

Elevated lipoprotein-associated phospholipase A2 is associated with progression of nonculprit lesions after percutaneous coronary intervention.

Xin H, Gong HP, Cai SL, Ning XF, Liu S, Chen ZY, Lian ZX, Zhang R, Zhang QF, Kang WQ, Ge ZM.

Tohoku J Exp Med. 2013 Jun;230(2):97-102.

18.

Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.

Li N, Li S, Yu C, Gu S.

Postgrad Med. 2010 Jul;122(4):200-5. doi: 10.3810/pgm.2010.07.2187.

PMID:
20675983
19.

Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers.

Ostadal P, Vondrakova D, Kruger A, Janotka M, Psotova H, Prucha M.

Lipids Health Dis. 2012 Nov 10;11:153. doi: 10.1186/1476-511X-11-153.

20.

The effect of statin therapy on lipoprotein associated phospholipase A2 levels.

Albert MA, Glynn RJ, Wolfert RL, Ridker PM.

Atherosclerosis. 2005 Sep;182(1):193-8.

PMID:
15982658

Supplemental Content

Support Center